AWA
IMDX

Arete Wealth Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Arete Wealth Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-625
Closed -$17K – 434
2020
Q3 		$17K Hold
625
– – ﹤0.01% 381
2020
Q2 		$24K Hold
625
– – ﹤0.01% 367
2020
Q1 		$31K Hold
625
– – 0.01% 335
2019
Q4 		$28K Hold
625
– – ﹤0.01% 387
2019
Q3 		$26K Buy
+625
New +$24.6K 0.01% 403

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arete Wealth Advisors's IMDX Position: Q4 2020 in Review

Arete Wealth Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 625 shares — an estimated $17K sold.

Arete Wealth Advisors first reported a position in IMDX in Q3 2019 and held it in 5 quarters. The position peaked at $31K in Q1 2020. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • Arete Wealth Advisors reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Arete Wealth Advisors sold 625 Insight Molecular Diagnostics shares in Q4 2020, an estimated $17K.
  • Arete Wealth Advisors first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 5 quarters.
  • Arete Wealth Advisors's Insight Molecular Diagnostics position peaked at $31K in Q1 2020.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on Arete Wealth Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.